REG - IXICO plc - Trading Update

IXICOAnnouncement

14/08/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240814:nRSN3341Aa&default-theme=true

RNS Number : 3341A  IXICO plc  14 August 2024

This announcement contains inside information as stipulated under the retained
EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR")
which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
The information is disclosed in accordance with the Company's obligations
under Article 17 of the UK MAR.

 

14 August 2024

IXICO plc

("IXICO" or the "Company")

 

Trading update for the year ending 30 September 2024

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience, announces a trading update for the year
ending 30 September 2024 ("FY24").

 

FY24 financial performance is expected to be ahead of market expectations
following new contract wins worth £5.8 million in the period since 31 March
2024 (IXICO's half-year end).

 

·    Full year FY24 revenue expected to be between £5.5 million and £5.9
million (2023: £6.7 million) reflecting growth of at least 20% in revenues
across the second half of the year as compared to the first half (H1 2024:
£2.5 million).

 

·    Year-end order book expected to increase and return to prior year end
levels (2023 FY: £14.8 million; H1 2024: £12.7 million) following the
signing of contracts and contract extensions.

 

This expected increase in revenues and contract wins will improve cash and
EBITDA performance as compared to the existing market expectations of £1.4
million cash and £2.1 million EBITDA loss respectively.

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "I am pleased
with the progress made by the Company since the half-year, with new contracts
signed underpinning revenue growth across the second half of the year.  In
parallel, we have continued to see a strengthening of our opportunities
pipeline and whilst we maintain a very close eye on costs, we are doing so in
a manner that avoids detriment to our core focus of delivering growth."

 

 

For further information please contact:

 

 IXICO plc                                                                                                           +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated adviser and sole broker)                                               +44 (0) 20 7397 8900
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Michael F Johnson / Tamar Cranford Smith / Charlie Combe (Sales and Corporate
 Broking)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSFUFUDELSEFA